Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | See remarks below. | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZIMMER BIOMET HOLDINGS, INC.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,231 |
Reported balance
After 2026-09-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-04 · Sale · Disposed 3,000 · Balance 65,231 F1: Includes 471 shares acquired under the Employee Stock Purchase Plan and pursuant to dividend reinvestment through July 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 471 shares acquired under the Employee Stock Purchase Plan and pursuant to dividend reinvestment through July 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2022 Filed Dec 15, 2022 21:09 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 10,459 | $128.56 | $1,344,586.03 |
DisclosureSEC source: 0001062993-22-023943 · form4.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,943 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on November 29, 2022. F3 · price: Reflects the weighted average price of 10,459 shares of common stock of Zimmer Biomet Holdings, Inc. sold in multiple transactions on December 13, 2022 with sale prices ranging from $128.00 to 128.98 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuance, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:09 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 11,522 | $70.97 | $817,716.34 |
DisclosureSEC source: 0001062993-22-023943 · form4.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on November 29, 2022. F2 · balance_after: Includes 341 shares acquired under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan and pursuant to dividend reinvestment between April 27, 2022 and October 31, 2022. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:01 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 35,149 | $0.00 Strike: $62.22 | $0.00 |
DisclosureSEC source: 0001062993-22-008198 · form4.xml · derivative · entry 5 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,149 shares Expires 2022-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on March 9, 2022. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:01 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 5,331 | $122.46 | $652,807.61 |
DisclosureSEC source: 0001062993-22-008198 · form4.xml · nonDerivative · entry 4 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,539 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on March 9, 2022. F5 · price: Reflects the weighted average price of 5,331 shares of common stock of Zimmer Biomet Holdings, Inc. sold in multiple transactions on March 17, 2022 with sale prices ranging from $122.37 to $122.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuance, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:01 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 29,518 | $121.90 | $3,598,232.39 |
DisclosureSEC source: 0001062993-22-008198 · form4.xml · nonDerivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,870 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on March 9, 2022. F4 · price: Reflects the weighted average price of 29,518 shares of common stock of Zimmer Biomet Holdings, Inc. sold in multiple transactions on March 17, 2022 with sale prices ranging from $121.37 to $122.365 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuance, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:01 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 300 | $120.69 | $36,207.51 |
DisclosureSEC source: 0001062993-22-008198 · form4.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,388 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on March 9, 2022. F3 · price: Reflects the weighted average price of 300 shares of common stock of Zimmer Biomet Holdings, Inc. sold in multiple transactions on March 17, 2022 with sale prices ranging from $120.29 to $120.90 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuance, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:01 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 35,149 | $62.22 | $2,186,970.78 |
DisclosureSEC source: 0001062993-22-008198 · form4.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on March 9, 2022. F2 · balance_after: Includes 387 shares acquired under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan and pursuant to dividend reinvestment between April 28, 2021 and January 27, 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:06 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-006630 · form4.xml · derivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,641 Underlying: Common Stock · 1,641 shares Expires 2024-03-01 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:06 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 4,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-006630 · form4.xml · derivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,442 Underlying: Common Stock · 4,442 shares Expires 2024-02-25 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:06 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 2,129 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-006630 · form4.xml · derivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,129 Underlying: Common Stock · 2,129 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 22:11 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantEmployee Stock Option (right to buy) · Derivative | 23,507 | $0.00 Strike: $120.82 | $0.00 |
DisclosureSEC source: 0001062993-22-005368 · form4.xml · derivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,507 Underlying: Common Stock · 23,507 shares Expires 2032-02-18 F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 23:38 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionRestricted Stock Units · Derivative | 310 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-002185 · form4.xml · derivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 310 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: Earned RSUs vested on February 26, 2021. F4 · derivative.expiration_date: Earned RSUs vested on February 26, 2021. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 23:38 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Tax withholdingCommon Stock | 106 | $163.92 | $17,375.52 |
DisclosureSEC source: 0001062993-21-002185 · form4.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,152 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 23:38 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 310 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-002185 · form4.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 134 shares acquired under the Zimmer Biomet Holdings, Inc. (the "Company") Employee Stock Purchase Plan and pursuant to dividend reinvestment between October 28, 2020 and January 27, 2021. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:54 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantEmployee Stock Option (right to buy) · Derivative | 22,044 | $0.00 Strike: $163.79 | $0.00 |
DisclosureSEC source: 0001062993-21-002093 · form4.xml · derivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,044 Underlying: Common Stock · 22,044 shares Expires 2031-02-25 F1 · derivative.exercise_date: Vests annually over four years in increments of 25% each year, commencing on February 25, 2022. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 22:05 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 310 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-001860 · form4.xml · derivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310 Underlying: Common Stock · 310 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 18, 2021, based on actual performance for 2020, the reporting person earned 310 RSUs. F3 · derivative.exercise_date: Earned RSUs will vest on February 26, 2021. F3 · derivative.expiration_date: Earned RSUs will vest on February 26, 2021. F2 · derivative.underlying_shares: On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 18, 2021, based on actual performance for 2020, the reporting person earned 310 RSUs. F2 · balance_after: On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 18, 2021, based on actual performance for 2020, the reporting person earned 310 RSUs. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:15 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,040 | $0.00 Strike: $60.01 | $0.00 |
DisclosureSEC source: 0001062993-20-005583 · form4.xml · derivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,040 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Vested annually over four years in increments of 25% each year, commencing on March 16, 2012. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:15 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 30,040 | $159.70 | $4,797,388.00 |
DisclosureSEC source: 0001062993-20-005583 · form4.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,814 F1 · shares: Securities acquired or sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Phipps on August 13, 2020. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 21:15 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 30,040 | $60.10 | $1,805,404.00 |
DisclosureSEC source: 0001062993-20-005583 · form4.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Securities acquired or sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Phipps on August 13, 2020. F2 · balance_after: Includes 296 shares acquired under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan and pursuant to dividend reinvestment between April 20, 2020 and October 28, 2020. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 20:45 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionRestricted Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000074 · edgar.xml · derivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: Earned RSUs vested on March 20, 2020. F3 · derivative.expiration_date: Earned RSUs vested on March 20, 2020. Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 20:45 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Tax withholdingCommon Stock | 583 | $88.45 | $51,566.35 |
DisclosureSEC source: 0000911916-20-000074 · edgar.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,518 F1 · shares: Represents shares withheld by the Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 20:45 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000074 · edgar.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:24 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionRestricted Stock Units · Derivative | 1,610 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000059 · edgar.xml · derivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: Earned RSUs vested on February 26, 2020. F4 · derivative.expiration_date: Earned RSUs vested on February 26, 2020. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:24 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Tax withholdingCommon Stock | 465 | $149.61 | $69,568.65 |
DisclosureSEC source: 0000911916-20-000059 · edgar.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,064 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:24 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 1,610 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000059 · edgar.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 197 shares acquired under the Zimmer Biomet Holdings, Inc. (the "Company") Employee Stock Purchase Plan and pursuant to dividend reinvestment between October 31, 2019 and January 31, 2020. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:34 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantEmployee Stock Option (right to buy) · Derivative | 22,984 | $0.00 Strike: $157.54 | $0.00 |
DisclosureSEC source: 0000911916-20-000036 · edgar.xml · derivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,984 Underlying: Common Stock · 22,984 shares Expires 2030-02-21 F1 · derivative.exercise_date: Vests annually over four years in increments of 25% each year, commencing on February 21, 2021. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 23:01 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,610 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000023 · edgar.xml · derivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,610 Underlying: Common Stock · 1,610 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F4 · shares: On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 13, 2020, based on actual performance for 2019, the reporting person earned 1,610 RSUs. F5 · derivative.exercise_date: Earned RSUs will vest on February 26, 2020. F5 · derivative.expiration_date: Earned RSUs will vest on February 26, 2020. F4 · derivative.underlying_shares: On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 13, 2020, based on actual performance for 2019, the reporting person earned 1,610 RSUs. F4 · balance_after: On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 13, 2020, based on actual performance for 2019, the reporting person earned 1,610 RSUs. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 23:01 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000023 · edgar.xml · derivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037 Underlying: Common Stock · 2,037 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: On March 20, 2018, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2018 - 2020, with an opportunity for interim payouts after 2018 and 2019 depending on actual performance. As determined on February 13, 2020, based on actual performance for 2018-2019, the reporting person earned 2,037 RSUs. F3 · derivative.exercise_date: Earned RSUs will vest on March 20, 2020. F3 · derivative.expiration_date: Earned RSUs will vest on March 20, 2020. F2 · derivative.underlying_shares: On March 20, 2018, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2018 - 2020, with an opportunity for interim payouts after 2018 and 2019 depending on actual performance. As determined on February 13, 2020, based on actual performance for 2018-2019, the reporting person earned 2,037 RSUs. F2 · balance_after: On March 20, 2018, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2018 - 2020, with an opportunity for interim payouts after 2018 and 2019 depending on actual performance. As determined on February 13, 2020, based on actual performance for 2018-2019, the reporting person earned 2,037 RSUs. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 20:35 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 7,000 | $138.28 | $967,932.00 |
DisclosureSEC source: 0000911916-19-000162 · edgar.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,722 F1 · price: Represents the sale of 7,000 shares in multiple sale transactions, ranging in price from $138.267 to $138.352 per share, resulting in a weighted average sale price of $138.276. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 20:19 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 32,800 | $0.00 Strike: $58.02 | $0.00 |
DisclosureSEC source: 0000911916-19-000160 · edgar.xml · derivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,800 shares Expires 2020-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Vested annually over four years in increments of 25% each year, commencing on March 16, 2011. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 20:19 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 32,800 | $140.00 | $4,592,000.00 |
DisclosureSEC source: 0000911916-19-000160 · edgar.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,722 Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 20:19 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 32,800 | $58.02 | $1,903,056.00 |
DisclosureSEC source: 0000911916-19-000160 · edgar.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 249 shares acquired under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan and pursuant to dividend reinvestement between April 26, 2019 and July 29, 2019. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 20:14 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionRestricted Stock Units · Derivative | 1,331 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-19-000082 · edgar.xml · derivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: Earned RSUs vested on March 20, 2019. F4 · derivative.expiration_date: Earned RSUs vested on March 20, 2019. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 20:14 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Tax withholdingCommon Stock | 381 | $127.03 | $48,398.43 |
DisclosureSEC source: 0000911916-19-000082 · edgar.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,473 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 20:14 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 1,331 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-19-000082 · edgar.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 265 shares acquired under the Zimmer Biomet Holdings, Inc. (the "Company") Employee Stock Purchase Plan and pursuant to dividend reinvestment between October 31, 2018 and January 31, 2019. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:32 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantEmployee Stock Option (right to buy) · Derivative | 23,940 | $0.00 Strike: $123.73 | $0.00 |
DisclosureSEC source: 0000911916-19-000065 · edgar.xml · derivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,940 Underlying: Common Stock · 23,940 shares Expires 2029-02-26 F1 · derivative.exercise_date: Vests annually over four years in increments of 25% each year, commencing on February 26, 2020. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:32 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,331 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-19-000040 · edgar.xml · derivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,331 Underlying: Common Stock · 1,331 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: On March 20, 2018, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2018 - 2020, with an opportunity for interim payouts after 2018 and 2019 depending on actual performance. As determined on February 15, 2019, based on actual performance for 2018, the reporting person earned 1,331 RSUs. F3 · derivative.exercise_date: Earned RSUs will vest on March 20, 2019. F3 · derivative.expiration_date: Earned RSUs will vest on March 20, 2019. F2 · derivative.underlying_shares: On March 20, 2018, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2018 - 2020, with an opportunity for interim payouts after 2018 and 2019 depending on actual performance. As determined on February 15, 2019, based on actual performance for 2018, the reporting person earned 1,331 RSUs. F2 · balance_after: On March 20, 2018, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2018 - 2020, with an opportunity for interim payouts after 2018 and 2019 depending on actual performance. As determined on February 15, 2019, based on actual performance for 2018, the reporting person earned 1,331 RSUs. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 20:33 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,100 | $0.00 Strike: $39.94 | $0.00 |
DisclosureSEC source: 0000911916-18-000173 · edgar.xml · derivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,100 shares Expires 2019-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Vested annually over four years in increments of 25% each year, commencing on February 17, 2010. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 20:33 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 30,100 | $132.37 | $3,984,276.80 |
DisclosureSEC source: 0000911916-18-000173 · edgar.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,258 F1 · shares: Securities acquired or sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Phipps on August 30, 2018. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 20:33 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 30,100 | $39.94 | $1,202,194.00 |
DisclosureSEC source: 0000911916-18-000173 · edgar.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Securities acquired or sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Phipps on August 30, 2018. F2 · balance_after: Includes 80 shares acquired under the Zimmer Biomet Holdings, Inc. (the "Company") Employee Stock Purchase Plan between February 1, 2018 and June 29, 2018 and 161 shares purchased between February 1, 2018 and July 31, 2018 under the dividend reinvestment plan for the Company's common stock. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 20:12 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantEmployee Stock Option (right to buy) · Derivative | 22,235 | $0.00 Strike: $114.44 | $0.00 |
DisclosureSEC source: 0000911916-18-000071 · edgar.xml · derivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,235 Underlying: Common Stock · 22,235 shares Expires 2028-03-20 F1 · derivative.exercise_date: Vests annually over four years in increments of 25% each year, commencing on March 20, 2019. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:37 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantEmployee Stock Option (right to buy) · Derivative | 25,485 | $0.00 Strike: $119.61 | $0.00 |
DisclosureSEC source: 0000911916-18-000045 · edgar.xml · derivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,485 Underlying: Common Stock · 25,485 shares Expires 2028-02-20 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:35 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $78.53 | $0.00 |
DisclosureSEC source: 0000911916-18-000026 · edgar.xml · derivative · entry 4 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,000 shares Expires 2018-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Vested annually over four years in increments of 25% each year, commencing on February 12, 2009. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:35 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 8,372 | $116.41 | $974,617.17 |
DisclosureSEC source: 0000911916-18-000026 · edgar.xml · nonDerivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,017 F3 · price: Represents the sale of 8,372 shares in multiple transactions, ranging in price from $116.05 to $116.78 per share, resulting in a weighted average sale price of $116.4139. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:35 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 12,454 | $115.64 | $1,440,136.97 |
DisclosureSEC source: 0000911916-18-000026 · edgar.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,389 F2 · price: Represents the sale of 12,454 shares in multiple transactions, ranging in price from $115.05 to $116.04 per share, resulting in a weighted average sale price of $115.6365. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 14:35 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 27,000 | $78.53 | $2,120,310.00 |
DisclosureSEC source: 0000911916-18-000026 · edgar.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 148 shares acquired under the Zimmer Biomet Holdings, Inc. (the "Company") Employee Stock Purchase Plan between June 30, 2017 and January 30, 2018 and 198 shares purchased between July 28, 2017 and January 29, 2018 under the dividend reinvestment plan for the Company's common stock. Read SEC document |
| May 05, 2017 Filed May 9, 2017 11:37 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,200 | $0.00 Strike: $90.61 | $0.00 |
DisclosureSEC source: 0000911916-17-000167 · edgar.xml · derivative · entry 4 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,200 shares Expires 2017-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Vested annually over four years in increments of 25% each year, commencing on May 9, 2008 Read SEC document |
| May 05, 2017 Filed May 9, 2017 11:37 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 1,200 | $117.34 | $140,808.00 |
DisclosureSEC source: 0000911916-17-000167 · edgar.xml · nonDerivative · entry 3 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,497 F1 · shares: Securities acquired or sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Phipps on August 16, 2016. Read SEC document |
| May 05, 2017 Filed May 9, 2017 11:37 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | SaleCommon Stock | 5,000 | $116.62 | $583,078.00 |
DisclosureSEC source: 0000911916-17-000167 · edgar.xml · nonDerivative · entry 2 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,697 F1 · shares: Securities acquired or sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Phipps on August 16, 2016. F3 · price: Represents the sale of 5,000 shares in multiple transactions, ranging in price from $116.33 to $117.01 per share, resulting in a weighted average sale price of $116.6156. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. Read SEC document |
| May 05, 2017 Filed May 9, 2017 11:37 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | Exercise / conversionCommon Stock | 6,200 | $90.61 | $561,782.00 |
DisclosureSEC source: 0000911916-17-000167 · edgar.xml · nonDerivative · entry 1 Phipps Chad F · CIK 0001346672 · Sr. VP/Gen Counsel/Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Securities acquired or sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Phipps on August 16, 2016. F2 · balance_after: Includes 4 shares acquired under the Zimmer Biomet Holdings, Inc. (the "Company") Employee Stock Purchase Plan between January 31, 2017 and May 1, 2017 and 69 shares purchased between January 28, 2017 and April 28, 2017 under the dividend reinvestment plan for the Company's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.